carzelesin

a cyclopropylpyrroloindole analog of U 73975; longer lasting than U 77779; structure in first source

Also Known As:

NSC 619029; U 80244; U-80244; 2-Benzofurancarboxamide, N-(2-((1-(chloromethyl)-1,6-dihydro-8-methyl-5-(((phenylamino)carbonyl)oxy)benzo(1,2-b:4,3-b')dipyrrol-3(2H)-yl)carbonyl)-1H-indol-5-yl)-6-(diethylamino)-, (S)-

Networked: 10 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Duocarmycins: 63
        carzelesin: 10
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Duocarmycins: 63
        carzelesin: 10
    - Benzofurans: 26
      - carzelesin: 10

Experts

1.	Aamdal, S: 1 article (01/2000)
2.	Awada, A: 1 article (01/2000)
3.	Calvert, H: 1 article (01/2000)
4.	Fumoleau, P: 1 article (01/2000)
5.	Hanauske, A R: 1 article (01/2000)
6.	Morant, R: 1 article (01/2000)
7.	Pavlidis, N: 1 article (01/2000)
8.	Punt, C: 1 article (01/2000)
9.	Sorio, R: 1 article (01/2000)
10.	Verweij, J: 1 article (01/2000)

Related Diseases

1.	Neoplasms (Cancer) 09/15/1992 - "Carzelesin was highly effective against this tumor and produced 97% tumor growth inhibition. " 01/01/1995 - "Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors." 01/01/2000 - "At this dose and schedule carzelesin did not yield activity in the types of tumors studied." 01/01/1995 - "At the highest dose [0.5 mg/kg, the dose producing 10% lethality (LD10)]), carzelesin significantly inhibited growth in four of six colon tumor lines, causing a high proportion of partial regressions in one of seven lines and complete regressions of VRC5 colon tumors. " 01/01/1995 - "Carzelesin was given as a single i.v. injection, and tumor volumes were determined at 7-day intervals. "
2.	Rhabdomyosarcoma 01/01/1995 - "Carzelesin given at the highest nonlethal dose level significantly inhibited the growth of each of six rhabdomyosarcomas, causing a high frequency of partial or complete regressions in four of six tumor lines. " 10/01/1996 - "Carzelesin (U-80244), one of the synthetic DNA minor groove binding cyclopropylpyrroloindole analogues, was selected for clinical development because of its high potency, promising antitumor activity in murine solid tumors and leukemia, and significant therapeutic efficacy against colon and rhabdomyosarcoma xenografts. " 01/01/1995 - "There was no apparent cross-resistance to carzelesin in two rhabdomyosarcomas selected for vincristine resistance (Rh12/VCR, Rh18/VCR) or in Rh28/LPAM xenografts selected for primary resistance to the bifunctional alkylating agent melphalan. "
3.	Leukemia 10/01/1996 - "Carzelesin (U-80244), one of the synthetic DNA minor groove binding cyclopropylpyrroloindole analogues, was selected for clinical development because of its high potency, promising antitumor activity in murine solid tumors and leukemia, and significant therapeutic efficacy against colon and rhabdomyosarcoma xenografts. "
4.	Melanoma (Melanoma, Malignant) 01/01/2000 - "Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)." 01/01/2000 - "Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. "
5.	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/01/2000 - "Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)." 01/01/2000 - "Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma. "

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Alkylating Agents
3.	Prodrugs
4.	Melphalan (Alkeran)
5.	U 76074
6.	adozelesin
7.	Topotecan (Hycamtin)
8.	Vincristine (Oncovin)
9.	Cisplatin (Platino)
10.	KW 2189

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)